Aadautech

Cancer Drug Discovery & Therapeutics Blog

Pancreatic cancer: a deadly disease

clock October 1, 2009 12:56 by author Dr. Nagaraj

What is Pancreatic Cancer?

The pancreas is a long, flat gland that lies in the abdomen behind the stomach. It produces enzymes that aid digestion and certain hormones that help maintain the proper level of blood sugar. The American Cancer Society estimates that in the U.S. in 2009, there will be 42,470 people diagnosed with pancreatic cancer and 35,420 deaths from pancreatic cancer, making it the nation's fourth leading cause of cancer death overall. Unlike other cancers, there is no screening test for pancreatic cancer. There are also no symptoms until the cancer has begun to spread, which accounts for the cancer's dismal survival rate.

Pancreas cancer remains one of the most lethal forms of human cancer, with a 5 year survival rate of only 3-5%. More than 80% of patients present with advanced disease at diagnosis and therefore are not candidates for potentially curative surgical resection. Gemcitabine, remains the standard approach for the treatment of locally advanced and metastatic pancreatic cancer since 1997 with a median survival of approximately 6 months.

Pancreatic cancer has been brought to the forefront by the diagnoses of several prominent figures, including the late actor Patrick Swayze, who died of pancreatic cancer in September 2009, Apple cofounder and CEO Steve Jobs, and U.S. Supreme Court Justice Ruth Bader Ginsburg. The lifetime risks of pancreatic cancer is about 1 in 76. Pancreatic cancer ranks as the fourth deadliest cancer.

Figure adapted from- http://www.webmd.com/cancer/pancreatic-cancer/default.htm 

Causes of Pancreatic Cancer

Although the exact cause of pancreatic cancer is not known, smoking is the main risk factor, with smokers 2-3 times more likely to have the disease than nonsmokers. Age is also related, with the disease usually striking after age 45.  Diabetes is also linked to pancreatic cancer, with about 10-20% of those diagnosed with the cancer having diabetes. Other risks include chronic pancreatitis and cirrhosis of the liver. And family history of pancreatic cancer, high fat diet, obesity, and lack of exercise can also play a part. 

Diagnosing Pancreatic Cancer

The challenge of this disease is finding it early. A doctor cannot see or feel a tumor during a routine exam. To help make the diagnosis (and determine the most appropriate treatment), imaging tests are performed (such as an ultrasound or CT scan) to view pictures of the abdomen and determine the extent of the problem. The green region shown in this colorized CT scan appears to be cancer in the pancreas and liver. The diagnosis comes from a biopsy — taking a tissue sample from the tumor — performed either with a needle through the skin or during an operation.

Stages of Pancreatic Cancer

Stage is a term used in cancer treatment to describe the extent of spread. The stages of pancreatic cancer exist partly to guide treatment, but also to classify patients for clinical trials. The stages of pancreatic cancer are:

  • Stage 0: No spread. Pancreatic cancer is limited to a single layer of cells in the pancreas. The pancreatic cancer is not visible on imaging tests or even to the naked eye.
  • Stage I: Local growth. Pancreatic cancer is limited to the pancreas, but has grown to be less than 2 centimeters across (stage IA) or greater than 2 centimeters (stage IB).
  • Stage II: Local spread. Pancreatic cancer has grown outside the pancreas, and/or has spread to nearby lymph nodes.
  • Stage III: Wider spread. The tumor has expanded into nearby major blood vessels or nerves. As yet, pancreatic cancer can't be seen in other organs.
  • Stage IV: Confirmed spread. Pancreatic cancer is found in distant organs.

Recent advances into the molecular pathogenesis of pancreatic cancer have allowed researchers to better understand the involvement of multiple pathways and defined mutations associated with this tumor. This molecular heterogenicity is a major reason for failure of many targeted therapy. However, research over the last few decades have has led us to belief that pancreatic cancers show a progression model similar to that of colon cancer

Figure 1. Histological images of benign pancreatic ductal epithelial cells, progressive PanIN lesions and invasive carcinoma, with associated genetic alterations (Figure adapted from: Ghaneh et al GUT 2007, 56, 1134)

Treatment: Chemotherapy

Chemotherapy uses drugs to destroy cancer cells by stopping them from growing or multiplying. Treatment may consist of just one drug or a combination of drugs. It may be given by mouth or by injection into a muscle or vein. The drugs enter the bloodstream and travel through the body, making chemotherapy a good choice for cancer that has spread. It is also useful after surgery to kill any cancer cells left behind.

Most if not all pancreatic cancer cllinical trials use gemcitabine-based chemotherapy in combination with a new study drug. It is likely that gemcitabine will continue to be a key drug in clinical trial design until another active agent is studied conclusively.

Pancreatic cancer clinical trials are necessary to determine whether new treatments developed in the laboratory are beneficial to people living with pancreatic cancer.  The United States Food and Drug Administration (FDA) monitors most clinical trials to protect the participants and the general public.  Ultimately, the FDA reviews and analyzes data from successful clinical trials to determine whether the experimental treatment should be approved for the treatment of a specific disease or disorder, such as pancreatic cancer.

Completed Phase III clinical trials of targeted therapies in combination with gemcitabine for pancreatic cancer are,

Drugs investigated

Mechanism of Treatment

Number of Patients

Median Survival (months)

Marimastat

vs Gemcitabine

MMPI

414

3.4-4.1

 5.5

Marimastat+Gemcitabine

vs Gemcitabine

MMPI

239

5.4

5.4

Tanomastat  

vs Gemcitabine

MMPI

277

3.74

6.59

Tipifarnib+Gemcitabine

vs Gemcitabine

RAS FTI

688

6.3

6.0

G17DT+Gemcitabine

vs Gemcitabine

Antibodies against Gastrin 17

394

5.8

6.6

Bevacizumab+Gemcitabine

vs Gemcitabine

Anti-VEGF antibody

602

5.7

6.0

Erlotinib+Gemcitabine

vs Gemcitabine

EGFR tyrosine kinase inhibitor

569

6.24

5.91

Cetuximab+Gemcitabine

vs Gemcitabine

Anti-EGFR antibody

766

6.5

6.0

Bevacizumab+Erlotinib + Gemcitabine

vs Erlotinib+Gemcitabine

Anti-VEGF antibody and EGFR tyrosine kinase inhibitor

607

 7.1 

6.0

Ongoing Phase III clinical trials for pancreatic cancer are,

1. Erlotinib, capecitabine and gemcitabine

2. Curcumin, celecoxib and gemcitabine

3. Axitinib and gemcitabine

4. Sorafenib and gemcitabine

5. GC1001, capecitabine and gemcitabine

6. Aflibercept and gemcitabine 

For more details about clinical trials conducted in the United States and around the world http://clinicaltrials.gov/ct2/home

Reference: Wong and Lemoine (2009). Nat. Rev. Gastroenterol. Hepatol. 6, 412

Getting Support

Living with pancreatic cancer isn't easy; a support system is critical to help cope with the emotional and practical aspects of this aggressive disease. Many avenues for support exist within the local community and beyond, both for the patient and their family and friends. These organizations exist to help navigate the day-to-day treatment issues and the "big picture" worries about the future.

Bookmark and Share Bookmark and Share Bookmark and Share

Be the first to rate this post

  • Currently 0/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5


Lung cancer development by cigarette smoking: Finding therapeutic target?

clock March 17, 2009 09:04 by author Dr. Nagaraj

Cigarette smoking has been identified as the second leading risk factor for death from any cause worldwide. In 2000, an estimated 4.83 million deaths were attributed to cigarette smoking globally, with nearly half occurring in the developing world. With a population of 1.3 billion, China is the world's largest producer and consumer of tobacco and bears a large proportion of deaths attributable to smoking worldwide (Gu et al 2009, NEJM, 360, pp150).

Lung cancer is the leading cause of death among smokers. In 2007, there were an estimated 213 380 new lung and bronchus cancer cases and 160 390 people died of this disease in the USA (Cancer Facts & Figures 2007). Epidemiological studies have demonstrated that most cases of lung cancer are directly attributable to cigarette smoking. Only 5-10% of all of the lung cancers occur in patients without a prior history of cigarette smoking . Compared to non-smokers, smokers have a 10 fold greater risk of dying from lung cancer and in heavy smokers this risk increases by 15-25 folds. Although associations between cigarette smoking and lung cancer are well documented, surprisingly little is known about the mechanistic basis of smoking-related lung cancer at the cellular level. This is due, in part, to the fact that cigarette smoke is a complex and dynamic mixture of more than 4,000 individual chemical constituents. Cigarette smoke has been shown to have multiple effects on gene expression primarily, the expression of xenobiotic-metabolizing, redox-regulating genes, tumor suppressor genes, oncogenes, and genes involved in the regulation of inflammation.

Nicotine is the chemical in cigarettes that makes people addictive. Higher levels of nicotine in a cigarette can make it harder to quit smoking. A report by the Massachusetts Department of Health found that the amount of nicotine in cigarettes has steadily increased over the last 6 years. Higher nicotine levels were found in all cigarette categories, including "light" brands. In addition to nicotine, cigarette contains over 19 known cancer-causing chemicals (most are collectively known as "tar") and more than 4,000 other chemicals.

Cigarette smoking, DNA adducts formation and mutation status in lung cancer:

 

Figure 1.



Figure 2 adapted from: American Cancer Society, 2007


Ciagerette and its toxic chemicals:



Figure 3 adapted from http://counties.cce.cornell.edu/wyoming/family/reality_check/cigarette.jpg

Some of the chemicals associated with cigarette smoke include ammonia, carbon dioxide, carbon monoxide, propane, methane, acetone, hydrogen cyanide and various carcinogens. Other chemicals that are associated with chewing or sniffing tobacco include aniline, naphthalene, phenol, pyrene, tar, and 2-naphthylamine.

 

Figure 4. Countries, States, and Provinces That Have Banned Smoking in Indoor Workplaces and Other Indoor Public Places. Legislation in some countries and regions (shown in green) allows for the possibility of a designated, enclosed, ventilated smoking room. Full bans are also in force in Rhode Island, Hawaii, Puerto Rico, Washington, DC, Bermuda, the British Virgin Islands, Bhutan, and the Australian Capital Territory; legislation allowing for designated smoking rooms is in force in Malta. Full bans will go into effect in Quebec in 2008 and in Montana, Utah, and Hong Kong in 2009; a law allowing for the possibility of designated smoking rooms will go into effect in Finland in 2009.

(Figure 4 adapted from Koh et al. 2007. The New England Journal of Medicine, 356 (15): 1496)



Smoking and epithelial to mesenchymal transition (EMT) pathway: which is the target pathway?


Figure 5. Epithelial to Mesenchymal Transition (EMT) and Smoke. Four main signaling pathways activated by smoke exposure may contribute to EMT. Shh is a ligand that binds to its receptor, Ptch. Binding of Hh inactivates Ptch and derepresses the transmembrane protein, Smo, resulting in positive Hh signaling. This includes DNA binding of the transcription factor Gli, and activation of its target genes, such as cyclin D and Myc. Wnt is another ligand that, when bound to its receptor, Frizzled (Fz), leads to inactivation of GSK3. This prevents proteosomal degradation of β-catenin, and leads to the translocation of β-catenin into the nucleus, where it increases protumor gene expression through complex formation with the transcription factor TCF/LEF1. In lieu of a soluble Wnt ligand, Wnt/β-catenin gene expression can be triggered by the release of β-catenin from disassembled junctions. Smoke-inducing interactions between β-catenin and the membrane glycoprotein, MUC1, appear to promote junction disassembly by out competing β-catenin for E-cadherin. ROS are produced through the activation of NADPH oxidase, and lead to the activation of the transcription factor NK-κB. The activation of NK-κB leads to decreased expression of E-cadherin through the activation of Snail and upregulated expression of Bcl2, an inhibitor of apoptosis. Smoke-induced ROS also activates the A disintegrin and metalloprotease (ADAM), TNF-α–converting enzyme, to cause cleavage of amphiregulin, a ligand for EGFR. Activation of EGFR leads to Ras/Raf/MAPK, PI3K/Akt, and Src signaling. TGF-β isoforms signal through Smads, RhoA, PI3K, and MAPK. TGF-β leads to activation of PAR6, with the subsequent loss of tight junctions through the degradation of RhoA. TGF-β–initiated activation of RhoA leads to cytoskeletal changes and increased migration.

(Figure 5 adapted from: Dasari et al., American Journal of Respiratory Cell and Molecular Biology. Vol. 35, pp. 3-9, 2006)

Smoking and Lung Cancer: Videos

http://www.youtube.com/watch?v=3Re7CwwCAw0

GREAT REASONS TO QUIT SMOKING

If you are looking for a reason to quit smoking, consider these points:

  • People who quit smoking, regardless of their age, live longer than people the same age who continue to smoke.
  • Smokers who quit before the age of 50 are twice as likely to survive the next 15 years as those who continue to smoke. Smokers who quit before the age of 35 avoid 90% of the health risk linked to smoking.
  • By quitting smoking, you reduce your risk for developing cancer of the lung, mouth, nasal cavities, pharynx (throat), larynx, esophagus, stomach, pancreas, liver, kidney, bladder, cervix, and some types of leukemia.
  • You also reduce your risk for developing heart disease, stroke, emphysema, chronic bronchitis, and stomach ulcers.
  • Smoking is expensive. A one-pack-a-day habit usually costs $2,000 to $3,000 per year.
  • Parents can set a good example for their kids by quitting. Parents and pregnant women who quit can protect their children and fetus from secondhand smoke.

American Cancer Society: http://www.cancer.org/

American Lung Association: http://www.lungusa.org/

National Cancer Institute Cancer Information Service: http://www.cancer.gov/

Bookmark and Share Bookmark and Share Bookmark and Share

Currently rated 5.0 by 2 people

  • Currently 5/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5



Bookmark and Share Bookmark and Share Bookmark and Share

About us

Aadautech

The Cancer Drug Discovery & Therapeutics Blog was started in January 2009. It updates therapeutic targets and drug discovery in the area of cancer. Most of what you read here are updates of recent and new research in cancer therapeutics. Got a cancer news story you think belongs here? Lets discuss. So if you have an interest in cancer and cancer related discovery, please register and join others like you in an ongoing, vibrant dialog.

Contact: aadautech@gmail.com


RECENT COMMENTS

Comment RSS

People's HealthBlogger Awards 2009
People's HealthBlogger Awards 2009 - Best 100 Winner!
Wellsphere


Sign in